Evidence map›Paper›PMID 37076782›Full record

ArticleESC heart failure2023

Global differences in acute heart failure treatment: analysis of the STRONG-HF site feasibility questionnaire.

Maria Novosadova, Lauren Gianchetti, Koji Takagi, Priyanka Morishetty, Lauren Gaeta, Christopher Edwards, Beth A Davison, Adrien Picod, Alexandre Mebazaa, Gad Cotter

Abstract read
In one paragraph

Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. High-intensity care for GDMT titration.Heart failure reviews · 2024
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maria NovosadovaMomentum Research, Inc., Durham, NC, USA.
Lauren GianchettiMomentum Research, Inc., Durham, NC, USA.
Koji TakagiMomentum Research, Inc., Durham, NC, USA.ORCID 0000-0003-0213-1509
Priyanka MorishettyMomentum Research, Inc., Durham, NC, USA.
Lauren GaetaMomentum Research, Inc., Durham, NC, USA.
Christopher EdwardsMomentum Research, Inc., Durham, NC, USA.
Beth A DavisonMomentum Research, Inc., Durham, NC, USA.
Adrien PicodInserm U942 MASCOT, Paris, France.
Alexandre MebazaaInserm U942 MASCOT, Paris, France.
Gad CotterMomentum Research, Inc., Durham, NC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsAcute heart failure (AHF) has an impact on human health worldwide. Despite guidelines for treatment and management of AHF, mortality rates remain high. The main objective of this study was to compare standard in-hospital treatment and management of AHF against current clinical guidelines and variations across regions.

methodsBetween February 2018 and May 2021, investigators were approached to participate in the STRONG-HF study. The lead investigator at 158 sites in 20 countries completed a site feasibility questionnaire. Sites were grouped by country into five different regions: Africa and the Middle East, Eastern Europe, Russia, South America, and Western Europe.

resultsAccording to the questionnaires, there are large differences in how patients present due to AHF and where in the hospital they are treated. There were significant differences in reported percentage of AHF patients receiving angiotensin converting enzymes inhibitors across the regions (P < 0.001), mostly due to prescription of more angiotensin II receptor blockers and angiotensin receptor-neprilysin inhibitors in South America and Western Europe. Reported beta-blocker use was high across all of the regions. Device therapy and percutaneous interventions were more common in Europe. Sites reported a 5 to 8 day length of stay, while in Russia most have a 10 to 12 day length of stay. Regions reported that AHF patients follow up with a community cardiologist or general practitioner post-discharge, although follow-up was commonly more than 1 month post discharge, and not all sites had the capability to measure natriuretic peptides post discharge.

conclusionsIn this analysis of feasibility questionnaires, most sites reported general adherence to ESC guidelines for treatment and management of AHF patients although percutaneous and device therapy was less common outside Europe and follow-up after discharge took place late and was not as extensive as recommended. There were wide variations seen within and across regions in some areas.

Indexed as

Heart FailureHospitalizationAftercareFeasibility StudiesHumansPatient DischargeSurveys and QuestionnairesAcute heart failureAdherenceFeasibility questionnaireGuidelinesRegions

Identifiers

PMID37076782
PMCPMC10375066

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.